Study of the Role of Soluble Inhibitor of Interleukin 22, Interleukin 22 Binding Protein (IL-22BP), in Chronic Inflammatory Bowel Disease

Nantes University Hospital52 enrolled

Overview

IL-22 is an IL-10 family cytokine that plays major actions to increase intestinal epithelial barrier function and regeneration during experimental colitis. IL-22 binding protein is a small, soluble, and secreted protein potently inhibiting IL-22 actions through preventing the binding with IL-22 Recepteur. This study aims at characterizing how IL-22 binding protein is regulated in Inflammatory bowel disease to better understand the way IL-22 acts on epithelial cells during flares of the disease.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Inflammatory Bowel Disease

Interventions

Non interventional studyOTHER

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria 1. Crohn's disease or Ulcerative colitis 2. Healthy controls paired for age and sex 3. Samples availability in the biobank 4. Signed consent 5. No (Immune Mediated Inflammatory Disorders other than Inflammatory bowel disease 6. No other conditions predicted or known to affect IL-22/IL-22 recepteur /IL-22 binding protein regulation 7. Availability of clinical data 8. Age \>18 y.o. 9. No pregnancy

Study of the Role of Soluble Inhibitor of Interleukin 22, Interleukin 22 Binding Protein (IL-22BP), in Chronic Inflammatory Bowel Disease

Overview

Conditions

Interventions

Eligibility

Outcomes

Primary Outcomes